MetLife Shin-Yokohama Building
9th Floor 3-8-11, Shin-Yokohama Kohoku-ku
Yokohama 222-0033
Japan
81 45 475 3887
https://www.reprocell.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 92
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Dr. Shuji Yokoyama Ph.D. | CEO, President & Representative Director | N/A | N/A | 1968 |
Mr. Daisuke Usui | COO & Director | N/A | N/A | 1973 |
Mr. Ramakrishna V. Modali | CEO of REPROCELL USA Ltd & CEO of Bioserve Biotechnologies India | N/A | N/A | N/A |
Dr. David Bunton | Chief Executive officer of REPROCELL Europe | N/A | N/A | N/A |
ReproCELL Incorporated provides stem cell research and drug discovery services in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, pluripotent stem cells, and synfire induced neurons; 3D cell culture; and labware. The company also provides research stem cell, genomics, clinical stem cell research, preclinical and drug discovery CRO, precision medicine, human tissue samples, clinical laboratory, diagnostic, and gene editing services. ReproCELL Incorporated was incorporated in 2003 and is based in Yokohama, Japan.
ReproCELL Incorporateds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.